Aurora Kinase inhibitors - The dawn of a new approach to cancer

Description: Cell cycle inhibitors represent a key approach to the treatment of cancer. Therapeutic agents have traditionally targeted early stages of the cell cycle (i.e., the G1/S phase checkpoint or the S phase) or mitotic spindle formation as exemplified by the alkaloids. Recently, a new approach to cell cycle regulation has emerged with the identification of the Aurora kinase family. This family plays a role in later stages of the cell cycle from the G2/M checkpoint all the way through to the mitotic checkpoint and late mitosis.

Aurora Kinase Inhibitors: The dawn of a new approach to cancer was written as a target evaluation/drug development update report. This analysis was intended to provide a framework for all organizations considering entry into this exciting field or those already in the field but who require competitive intelligence within the area. The report:

- Introduces the Aurora kinases
- Analyzes the proof of concept supporting the development of aurora kinase inhibitors for the treatment of cancer
- Discusses mechanism of action
- Evaluates drugs in development
- Provides strategic guidance on kinase selectivity
- Discusses the promise and risks of kinase inhibitors
- Offers competitive intelligence discussing how Aurora kinase inhibitors would fit into the current oncology treatment area.

The report compares this class with existing and emerging classes and evaluates the part that Aurora kinase inhibitors could play in the combinatorial approach to cancer.

Contents:

1. Summary
2. Background
3. The Protein Kinases
   Tyrosine Kinases - Targets of the First Approved Kinase Inhibitors
   The Emergence of Serine-Threonine Kinases
   Genetics & Biochemistry of the Aurora kinases
   Identification of the Aurora Kinases
4. Physiological Role of the Aurora Kinases
5. Overexpression/Altered Activity of Aurora Kinases in Pathological States
6. Cellular Consequences of Overexpression/Altered Activity of Aurora Kinases
7. In vitro Effect of Aurora Kinase Inhibition
8. Development of Aurora Kinase Inhibitors
9. Strategic & Competitive Analysis
   Issues surrounding the development of Aurora Kinase inhibitors
   Can Aurora kinase inhibitors be considered targeted anticancer agents?
   Interaction with other therapeutics
   Would inhibitors be expected to be chemopreventative or therapeutic?
   Is mitotic interruption desirable or should our focus be reinstating the G2/M checkpoint?
   Which Aurora kinases should be targeted?
   Competitive analysis
Antimetabolites
Plant alkaloids
Integration of Aurora kinase inhibitors into combination therapies including established cytotoxic agents

Ordering:
Order Online - http://www.researchandmarkets.com/reports/306450/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Aurora Kinase inhibitors - The dawn of a new approach to cancer
Web Address: http://www.researchandmarkets.com/reports/306450/
Office Code: SCD22DZK

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic</td>
<td>USD 737</td>
</tr>
<tr>
<td>Electronic (PDF)</td>
<td>USD 1273</td>
</tr>
<tr>
<td>Enteprisewide</td>
<td></td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: __________________________ Last Name: __________________________
Email Address: * __________________________
Job Title: __________________________
Organisation: __________________________
Address: __________________________
City: __________________________
Postal / Zip Code: __________________________
Country: __________________________
Phone Number: __________________________
Fax Number: __________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets, Guinness Center, Taylors Lane, Dublin 8, Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ________________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World